NIGM is a form of Non-Invasive Prenatal Testing (NIPT) based on next-generation sequencing using cell-free DNA (cfDNA) in maternal blood to evaluate possible chromosomal conditions in pregnancy. It can be performed as early as 9 gestational weeks using a single tube of blood.
NIGM offers the prenatal test with a focused and clinically relevant menu that screens for chromosomal aneuploidies, specific sex chromosome aneuploidies, and pathogenic microdeletions/duplications.
Simple 
Accurate Proven >99% sensitivity based on a test of more than 70,000 pregnancies
Fast & Convenient - Quick test from sample preparation to report generation within 24 hours
- Simplified operation: Automated and localized data analysis and report
Flexible - Compatible with most standard NGS library prep kits and bioinformatics tools
- Offering flexible options for both manual and automated workflows
Preimplanation Genetic Testing for Aneuploidy (PGT-A), which is applied to identify chromosomal abnormalities and that represents the broadest indication to preimplantation genetics at present. Preimplantation genetic testing for aneuploidy identififies chromosomal abnormalities in embryo samples for the research of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). These genetic insights may increase the probability of success for future pregnancies and healthier future generations.
Easy-to-use Automated and simplified sequencing and data analysis workflow
Fast Quick test from sample preparation to final report within 24 hours
Flexible Compatible with common used NGS library preparation kits and bioinformatics tools
Sensitive Accurately detect different types of chromosomal mutations even in a low copies
Clinical diagnostic whole‐exome sequencing (WES) is a powerful tool for patients with undiagnosed genetic disorders. WES employs high-throughput sequencing of more than 20,000 genes per individual, enriched through sequence capture technology. WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of known disease-causing variants. It allows for molecular diagnosis of genetic diseases and enables the exploration of novel mutations and new pathogenic mechanisms. Compared to whole genome sequencing, WES has the advantage of a greater sequencing depth and delivers more effective data.For patients with symptoms of genetic disorders, clinical exome sequencing plays an important role in quickly identifying potential variants. Clinical exome sequencing offers a one-step solution for challenging issues, such as diagnosing patients with genetic heterogeneity or atypical presentation, where it is unclear which genes are causing the specific genetic condition.
Easy-to-use Automated and simplified sequencing and data analysis workflow
Fast Quick test from sample preparation to final report within 2 weeks
